Aerie pharmaceuticals announces acceptance of its investigational new drug application for ar-15512 (trpm8 agonist) eye drop for dry eye disease

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the u.s. food and drug administration (fda) has reviewed the investigational new drug application (ind) for ar-15512 (trpm8 agonist) eye drop for dry eye and it is now in effec
AERI Ratings Summary
AERI Quant Ranking